Company attributes
Other attributes
ImmunoGen is a company that is targeting a better life for people with cancer by keeping cancer from disrupting peoples' lives. Its scientists have expertise in target selection, including assessment of appropriate levels of expression on tumor versus normal tissue and rate of internalization. The company has established knowledge in the development of tumor-targeting antibodies, having created one of the few CD37-targeting antibodies.
ImmunoGen was founded with $3 million in seed financing. ImmunoGen’s labs are working on the first generation of antibody-drug conjugates (ADCs). For 40 years, ImmunoGen has been researching and developing ADCs that are designed to disrupt the progression of cancer.
The company's portfolio of toxins comprises of different types of cancer-killing agents that include tubulin-acting maytansinoids and its DNA-acting IGNs, which are more potent than traditional chemotherapy.
